logo

Astellas Pharma Inc. (ALPMY)



Trade ALPMY now with
  Date
  Headline
10/28/2019 9:03:01 AM FDA Grants Fast Track Designation To Astellas For Development Of ASP1128 For Patients At Risk For Acute Kidney Injury
10/25/2019 3:04:12 AM EC Approves Astellas' XOSPATA As Monotherapy For Patients With Relapsed Or Refractory AML With FLT3 Mutation
9/20/2019 8:27:21 AM Astellas Gets Positive CHMP Opinion For XOSPATA As A Monotherapy For Relapsed Or Refractory AML With A FLT3 Mutation
9/20/2019 3:10:45 AM X5 Retail Announces Opening Of First New-concept Pyaterochka Store
9/20/2019 3:01:37 AM Evrenzo Tablets Approved In Japan For Anemia Associated With Chronic Kidney Disease In Dialysis Patients
9/16/2019 8:02:47 AM Seattle Genetics And Astellas: FDA Grants Priority Review For Enfortumab Vedotin BLA
8/6/2019 12:06:07 AM Astellas Initiates Phase 3 Clinical Trials For Fezolinetant In Postmenopausal Women With Vasomotor Symptoms
7/16/2019 8:19:27 AM Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA For Enfortumab Vedotin
7/16/2019 8:09:39 AM Seattle Genetics, Astellas Announce Submission Of BLA For Enfortumab Vedotin
7/10/2019 9:01:48 AM Astellas Names Chelsea Glinski National VP, Oncology Sales, Astellas US
6/3/2019 7:35:06 AM Astellas Pharma, Seattle Genetics Announce Enfortumab Vedotin Produced Tumor Response Rate Of 44%
5/30/2019 8:02:00 AM Astellas Says FDA Approves Supplemental New Drug Application Adding Overall Survival Data For XOSPATA
  
 
>